Biblio

Author Title [ Type

] Year

Filters: Author is Elena, Chiara [Clear All Filters]

Journal Article

Aberer E, Sperr WR, Bretterklieber A, Avian A, Hadzijusufovic E, Kluin-Nelemans HC, Elberink HOude, van Anrooij B, Niedoszytko M, Lange M, et al. Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis (ECNM). J Invest Dermatol. 2021.

Malcovati L, Ambaglio I, Elena C. The genomic landscape of myeloid neoplasms with myelodysplasia and its clinical implications. Curr Opin Oncol. 2015.

Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, Castagnetti F, Galimberti S, Bonifacio M, Annunziata M, Gozzini A, et al. The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib. Ann Hematol. 2023.

Trojani A, Pungolino E, Dal Molin A, Lodola M, Rossi G, D'Adda M, Perego A, Elena C, Turrini M, Borin L, et al. Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment. PLoS One. 2019;14(7):e0218444.

Lübke J, Schmid A, Christen D, Elberink HNGOude, Span LFR, Niedoszytko M, Górska A, Lange M, Gleixner KV, Hadzijusufovic E, et al. Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM. Blood Adv. 2024.